Ten year outcomes in three vessel disease treated by CABG versus PCI in an Eastern European registry

东欧注册研究显示,接受冠状动脉旁路移植术(CABG)与经皮冠状动脉介入治疗(PCI)治疗的三支血管病变患者,十年随访结果显示,CABG 与 PCI 疗效相当。

阅读:1

Abstract

Long-term outcomes in ischemic heart disease are historically underreported in Eastern Europe. Our aim was to report 10-year survival and to identify outcome predictors in patients with three-vessel coronary artery disease (CAD) treated by either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in an Eastern European center. Patients treated for three-vessel CAD with CABG or PCI with drug-eluting stents between August 2013 and February 2025 in a Romanian tertiary hospital were selected for inclusion in this study. All-cause and cardiovascular-cause survival data were available as of May 2025. A total of 7014 patients were included, of which 2759 (39.3%) were treated with CABG and 4255 (60.6%) were treated with PCI. The 10-year all-cause and cardiovascular-cause survival rates were 50.5% and 57.7%, respectively. The CABG group had both higher all-cause and cardiovascular cause mortality than the PCI group (log-rank p = 0.01 and p = 0.03, respectively). CABG was an independent protective predictor, with patients having at least one arterial graft performing better survival than patients having venous grafts only. PCI was an independent predictor of events, with patients undergoing single coronary stenting having better survival than patients undergoing multiple coronary stenting. The 10-year survival after CABG or PCI is lower in Eastern Europe than that reported by other Western registries. However, at the 10-year follow-up, CABG associated with lower incidence of all-cause and cardiovascular-cause death when compared to PCI. These results provide contemporary evidence regarding the long-term benefit of CABG in patients with complex CAD in a real-world scenario.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。